Does the BCG Vaccine Protect Against Coronavirus? Applying an Economist’s Toolkit to a Medical Question

Richard Bluhm and Maxim Pinkovskiy

No 20200511, Liberty Street Economics from Federal Reserve Bank of New York

Abstract: As COVID-19 has spread across the globe, there is an intense search for treatments and vaccines, with numerous trials running in multiple countries. Several observers and prominent news outlets have noticed that countries still administering an old vaccine against tuberculosis—the Bacillus Calmette-Guérin (BCG) vaccine—have had fewer coronavirus cases and fewer deaths per capita in the early stages of the outbreak. But is that correlation really strong evidence that the BCG vaccine provides some defense against COVID-19? In this post, we look at the incidence of coronavirus cases along the former border between East and West Germany, using econometric techniques to investigate whether historical differences in vaccination policies account for the lower level of infection in the former East.

Keywords: BCG vaccine; Coronavirus; Germany; COVID-19 (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
Date: 2020-05-11
New Economics Papers: this item is included in nep-hea
References: Add references at CitEc
Citations:

Downloads: (external link)
https://libertystreeteconomics.newyorkfed.org/2020 ... nst-coronavirus.html Full text (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:fip:fednls:87946

Ordering information: This working paper can be ordered from

Access Statistics for this paper

More papers in Liberty Street Economics from Federal Reserve Bank of New York Contact information at EDIRC.
Bibliographic data for series maintained by Gabriella Bucciarelli ().